This document discusses the Falsified Medicines Directive (FMD) in the European Union. It provides details on the following key points: 1. The FMD requires medicines at risk of falsification to have unique codes and tamper-evident packaging to enable verification of authenticity. 2. Implementation requirements are being determined through Delegated Acts, which will specify uniform rules across all EU member states. 3. The Delegated Acts are expected to be adopted in August 2015 and published by the end of 2015, giving member states three years to implement safety features and authentication systems.